{"classes":[{"categories":[{"measurements":[{"comment":"Median and 95% CI could not be calculated since there is only one participant for Cohort 4.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Since the upper confidence limits for the survivor function lies above 0.5, it is not possible to estimate the upper confidence limit for the median for Cohort 5.","groupId":"OG001","lowerLimit":"2.80","upperLimit":"NA","value":"11.90"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Duration of overall response was calculated similarly to DCR but was assessed the time in months between documentation of the first response of PR or better until the date of relapse, death, whichever is earlier. The estimation of median duration of overall response was done by Kaplan-Meier method. The median duration of overall response is defined as the time at which 50% of the participants in a study have experienced the event of interest (relapse or death). Given the presence of only a single participant in the sample, there is an absence of variability in outcomes, and therefore, it was not possible to ascertain a time point at which half of the participants have experienced the event. Hence, median value could not be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with R/R AML that is naïve to prior hypomethylating therapy and IDH1 inhibitor therapy received combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG000","title":"Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants with R/R AML/MDS that have inadequately responded to or have progressed on prior hypo-methylating therapy received combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG001","title":"Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)"}],"paramType":"MEDIAN","populationDescription":"FAS included all the participants who were enrolled in the study and have received at least one dose of FT-2102. This outcome measure is applicable only for cohort 4 and 5. Here, Overall Number of Participants Analyzed = participants with overall response for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Phase 2: From the documentation of the first response of PR or better until the date of relapse, death, whichever is earlier (up to 82 months)","title":"Phase 2, Cohort 4 and Cohort 5: Duration of Overall Response for Myelodysplastic Syndrome (MDS)","type":"SECONDARY","unitOfMeasure":"Months"}